Literature DB >> 18682601

IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma.

Katherine R Calvo1, Bhavana Dabir, Alexandra Kovach, Christopher Devor, Russell Bandle, Amelia Bond, Joanna H Shih, Elaine S Jaffe.   

Abstract

Follicular lymphoma (FL) is characterized by constitutive expression of Bcl-2 as a consequence of t(14;18). Evidence suggests factors in the lymph node microenvironment, related to intratumoral T cells, macrophages, and dendritic cells, play a role in the disease process. We generated proteomic cytokine profiles of FL (N = 50) and follicular hyperplasia (FH; N = 23). A total of 10 cytokines were assayed using ultrasensitive multiplex enzyme-linked immunosorbent assays: IL-1beta, IL-2, IL-4, IL-5, IL-8, IL-10, IL-13, IL-12p70, tumor necrosis factor-alpha, and interferon-gamma. Each cytokine showed overall lower protein concentrations in FL, with the exception of IL-4, which was nearly 5 times higher in FL than FH (P = .005). Using reverse-phase protein microarrays (RPMAs), we evaluated the activation state of several intracellular signaling proteins downstream of cytokine receptors. Basal Erk phosphorylation was approximately 4 times greater in FL than FH (P < .001), with similar findings for Mek; Stat-6 showed weak basal phosphorylation that was approximately twice as high in FL than in FH (P = .012). In conclusion, the FL microenvironment contains increased levels of IL-4, with prominent tumor basal phosphorylation of Erk. These findings suggest IL-4, Erk, and possibly Stat-6 may play a role in the biology of FL and may serve as targets for future therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18682601      PMCID: PMC2954752          DOI: 10.1182/blood-2008-02-138933

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  59 in total

1.  Cutting edge: STAT6 serves as a positive and negative regulator of gene expression in IL-4-stimulated B lymphocytes.

Authors:  Andreas J Schroder; Paul Pavlidis; Akinori Arimura; Danielle Capece; Paul B Rothman
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

2.  Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.

Authors:  Kojo S J Elenitoba-Johnson; Stephen D Jenson; Robert T Abbott; Robert A Palais; Sandra D Bohling; Zhaosheng Lin; Sheryl Tripp; Paul J Shami; Lai Y Wang; Robert W Coupland; Rena Buckstein; Bayardo Perez-Ordonez; Sherrie L Perkins; Ian D Dube; Megan S Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-19       Impact factor: 11.205

Review 3.  Protein microarrays: meeting analytical challenges for clinical applications.

Authors:  Lance A Liotta; Virginia Espina; Arpita I Mehta; Valerie Calvert; Kevin Rosenblatt; David Geho; Peter J Munson; Lynn Young; Julia Wulfkuhle; Emanuel F Petricoin
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

4.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

5.  Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays.

Authors:  Hervé Husson; Elizabeth G Carideo; Donna Neuberg; Joachim Schultze; Olivier Munoz; Peter W Marks; John W Donovan; Antoinette C Chillemi; Peter O'Connell; Arnold S Freedman
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

6.  Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma.

Authors:  J Fitzgibbon; D Grenzelias; J Matthews; T A Lister; R K Gupta
Journal:  Br J Haematol       Date:  1999-11       Impact factor: 6.998

7.  Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.

Authors:  Brian F Skinnider; Andrew J Elia; Randy D Gascoyne; Bruce Patterson; Lorenz Trumper; Ursula Kapp; Tak W Mak
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

Review 8.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

9.  Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma.

Authors:  Christiane Copie-Bergman; Marie-Laure Boulland; Catherine Dehoulle; Peter Möller; Jean-Pierre Farcet; Martin J S Dyer; Corinne Haioun; Paul-Henri Roméo; Philippe Gaulard; Karen Leroy
Journal:  Blood       Date:  2002-11-21       Impact factor: 22.113

10.  Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.

Authors:  Bret B Friday; Alex A Adjei
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

View more
  26 in total

Review 1.  The host-tumor interface in B-cell non-Hodgkin lymphoma: a new world to investigate.

Authors:  Nicolas Rachinel; Gilles Salles
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

Review 2.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

3.  DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma.

Authors:  Rada Amin; Frédéric Mourcin; Fabrice Uhel; Céline Pangault; Philippe Ruminy; Loic Dupré; Marion Guirriec; Tony Marchand; Thierry Fest; Thierry Lamy; Karin Tarte
Journal:  Blood       Date:  2015-08-13       Impact factor: 22.113

4.  MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response.

Authors:  Weixin Wang; Meghan Corrigan-Cummins; Justin Hudson; Irina Maric; Olga Simakova; Sattva S Neelapu; Larry W Kwak; John E Janik; Barry Gause; Elaine S Jaffe; Katherine R Calvo
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

Review 5.  The differential expression of IL-4 and IL-13 and its impact on type-2 immunity.

Authors:  Katherine Bao; R Lee Reinhardt
Journal:  Cytokine       Date:  2015-06-11       Impact factor: 3.861

6.  Activating STAT6 mutations in follicular lymphoma.

Authors:  Mehmet Yildiz; Hongxiu Li; Denzil Bernard; Nisar A Amin; Peter Ouillette; Siân Jones; Kamlai Saiya-Cork; Brian Parkin; Kathryn Jacobi; Kerby Shedden; Shaomeng Wang; Alfred E Chang; Mark S Kaminski; Sami N Malek
Journal:  Blood       Date:  2014-11-26       Impact factor: 22.113

7.  Synchronous malignant B-cell lymphoma and gastric tubular adenocarcinoma associated with paraneoplastic cutaneous vasculitis: hypereosinophilic syndrome with mixed cryoglobulinemia is an important sign of paraneoplastic syndrome.

Authors:  Kazuhisa Nozawa; Hiroshi Kaneko; Tomoyasu Itoh; Yoko Katsura; Masaaki Noguchi; Fujihiko Suzuki; Yoshinari Takasaki; Hideoki Ogawa; Kenji Takamori; Iwao Sekigawa
Journal:  Rare Tumors       Date:  2009-12-28

8.  Global regulation of promoter melting in naive lymphocytes.

Authors:  Fedor Kouzine; Damian Wojtowicz; Arito Yamane; Wolfgang Resch; Kyong-Rim Kieffer-Kwon; Russell Bandle; Steevenson Nelson; Hirotaka Nakahashi; Parirokh Awasthi; Lionel Feigenbaum; Herve Menoni; Jan Hoeijmakers; Wim Vermeulen; Hui Ge; Teresa M Przytycka; David Levens; Rafael Casellas
Journal:  Cell       Date:  2013-05-23       Impact factor: 41.582

9.  Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment.

Authors:  Seema Rawal; Fuliang Chu; Min Zhang; Hyun Jun Park; Durga Nattamai; Shibichakravarthy Kannan; Rakesh Sharma; David Delgado; Tina Chou; Heather Y Lin; Veerabhadran Baladandayuthapani; Amber Luong; Francisco Vega; Nathan Fowler; Chen Dong; R Eric Davis; Sattva S Neelapu
Journal:  J Immunol       Date:  2013-05-17       Impact factor: 5.422

Review 10.  The tumour microenvironment in B cell lymphomas.

Authors:  David W Scott; Randy D Gascoyne
Journal:  Nat Rev Cancer       Date:  2014-07-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.